401 results on '"Dalakas, Marinos C."'
Search Results
2. Post-COVID Small Fiber Neuropathy, Implications of Innate Immunity, and Challenges on IVIG Therapy
3. Advances in the therapeutic algorithm for myasthenia gravis
4. Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies
5. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies
6. Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies
7. Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases
8. Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies
9. Progressive multifocal fibrosing neuropathy: description of a novel disease
10. Severe Stiff-Person Syndrome After COVID
11. Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy
12. N2 Year in Review
13. Severe Stiff-Person Syndrome After COVID: The First Video-Documented COVID Exacerbation and Viral Implications
14. Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology
15. Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID
16. Complement in neurological disorders and emerging complement-targeted therapeutics
17. Anti-Neuronal Antibodies Within the IVIg Preparations: Importance in Clinical Practice
18. Treatment for inclusion body myositis
19. IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti–B Cell Therapies
20. Immunotherapy in myasthenia gravis in the era of biologics
21. LGI1 encephalitis with squamous lung-cell carcinoma: Resolution after tumor resection
22. N2 year in review
23. Spatial and Ecological Factors Modulate the Incidence of Anti-NMDAR Encephalitis—A Systematic Review
24. Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria
25. Anti–SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients
26. Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder
27. Late-onset stiff-person syndrome: challenges in diagnosis and management.
28. N2 year in review
29. Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis
30. Therapies in Stiff-Person Syndrome
31. MiRP2 Forms Potassium Channels in Skeletal Muscle with Kv3.4 and Is Associated with Periodic Paralysis
32. Objectivity, Practicality, and Significance of Practice Guidelines for the Practicing Neurologists: What We Learnt From Consensus Criteria in CIDP, Myasthenia Gravis and Inflammatory Myopathies
33. Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
34. Objectivity, practicality, and significance of practice guidelines for the practicing neurologists: What we learnt from consensus criteria in CIDP, Myasthenia Gravis and Inflammatory Myopathies
35. Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?
36. Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations
37. Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease
38. Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials
39. Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity
40. Efficacy of Intravenous Immunoglobulin in Neurological Diseases
41. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity
42. Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome
43. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy:Implications for Complement-Targeted Therapies
44. Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis.
45. Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis
46. Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future
47. IgG4-Mediated Neurologic Autoimmunities
48. Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate
49. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders
50. Intravenous immunoglobulin in neurology—mode of action and clinical efficacy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.